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The steroid hormone, 17β-estradiol (E2), plays critical role in various cellular processes
such as cell proliferation, differentiation, migration and apoptosis, and is essential for
reproduction and mammary gland development. E2 actions are mediated by two classical
nuclear hormone receptors, estrogen receptor α and β (ERs). The activity of ERs depends
on the coordinated activity of ligand binding, post-translational modifications (PTMs), and
importantly the interaction with their partner proteins called “coregulators.” Because
coregulators are proved to be crucial for ER transcriptional activity, and majority of breast
cancers are ERα positive, an increased interest in the field has led to the identification of
a large number of coregulators. In the last decade, gene knockout studies using mouse
models provided impetus to our further understanding of the role of these coregulators
in mammary gland development. Several coregulators appear to be critical for terminal
end bud (TEB) formation, ductal branching and alveologenesis during mammary gland
development. The emerging studies support that, coregulators along with the other ER
partner proteins called “pioneer factors” together contribute significantly to E2 signaling
and mammary cell fate. This review discusses emerging themes in coregulator and
pioneer factor mediated action on ER functions, in particular their role in mammary gland
cell fate and development.
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INTRODUCTION
Mammary gland development occurs postnatally unlike other
human organs (Russo and Russo, 2004). The ovarian hormones,
17β-estradiol (hereafter referred to as E2) and progesterone play a
pivotal role in mammary gland development. Although prenatal
development ofmammary gland is relatively independent of these
steroid hormones, pronounced growth occurs during puberty
which requires E2. Hence, the hormone-dependent mammary
gland development occurs only after puberty. The ovarian hor-
mones impact profound morphogenetic changes in the devel-
opment of gland by inducing ductal elongation, side branching,
terminal end bud (TEB) formation and alveologenesis (Brisken
and O’malley, 2010).
E2 exerts its biological functions through specific ligand-
inducible nuclear receptors, namely estrogen receptors (ERs)
ERα and ERβ. These receptors are encoded by genes located
on two different chromosomes and share considerable sequence
homology (Nilsson et al., 2001). These proteins regulate the tran-
scription of a diverse array of target genes during development
and, in response to specific physiological and pathological signals
(Klinge, 2000). Knockout mouse studies have clearly demon-
strated that ERα is indispensible for the postnatal development of
mammary gland while ERβ is not (Mueller et al., 2002; Mallepell
Abbreviations: TEBs, terminal end buds; KO, knockout; Tg mice, transgenic mice;
ERα, estrogen receptor alpha; Esr1, estrogen receptor alpha gene 1; SHR, steroid
hormone receptor; PTMs, post-translational modifications; PgR, progesterone
receptor; MaSC, mammary stem cells.
et al., 2006; Feng et al., 2007). The canonical action of the ER
involves binding to its ligand with a concomitant dissociation
from HSP chaperone proteins, receptor dimerization, nuclear
entry and binding to E2 response elements (EREs) located within
the promoter/enhancer regions of the target genes to regulate
transcription (Klein-Hitpass et al., 1988; Echeverria and Picard,
2010). Accumulating evidence suggests that ERα is preferentially
recruited at enhancer regions of target genes upon E2 stimula-
tion (Carroll et al., 2005; Welboren et al., 2009; Gertz et al., 2012;
Ross-Innes et al., 2012; Xiao et al., 2012). These enhancer ele-
ments modulate target gene expression by forming chromatin
loops (Lieberman-Aiden et al., 2009; Sanyal et al., 2012). This is
strengthened by the fact that ERα depletion leads to transcrip-
tional repression and loss of chromatin loops, thereby supporting
the notion that ERα indeed participates in chromatin loop forma-
tion in the breast cancer cells (Fullwood et al., 2009).
In contrast, a recent study suggests that unliganded ERα also
binds to large number of chromatin sites in breast cancer cells
and, this binding is specifically linked to genes with developmen-
tal functions (Caizzi et al., 2014). ERα can also affect gene tran-
scription indirectly through its physical interaction with other
transcription factors, such as activator protein 1 (AP1), SP1,
nuclear factor-κB (NF-κB) and E2F1 (Safe, 2001). Functionality
of the ERα is further regulated by the post-translational mod-
ifications (PTMs) and its cooperative interaction with a special
category of proteins called “coregulators,” which exhibit with
a coactivator or corepressor activities (Lonard and O’malley,
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2007). The importance of coregulators in ER functions as demon-
strated in vitro generated intense research to decipher their role in
mammary gland development. In vivo characterization of several
coregulators of ERα provides further impetus to their biological
roles in normal and pathological conditions.
THE CONCEPT OF “COREGULATOR”
The concept of coregulator was introduced to the field of nuclear
receptors approximately two decades ago (Onate et al., 1995).
Though there was confusion initially about classifying these
molecules as cofactors based on their similarity to a cofactor of an
enzyme, they were later referred as “coregulators” (O’malley and
Mckenna, 2008). Unlike the function of a cofactor to an enzyme,
coregulator acts as a bridging or helper molecule that helps in
forming large protein complexes to modulate appropriate activ-
ity on target gene chromatin. Although enzymes exhibit absolute
cofactor specificity in a tissue-independent manner, steroid hor-
mone receptors (SHRs) utilizes different tissue-specific coregula-
tors for their activity in a spatio-temporal manner. SHRs being
transcription factors, the coregulators may positively or nega-
tively influence the receptor’s transcriptional activity by modi-
fying the target gene chromatin. The coregulators that enhance
the transcriptional activity of SHRs are called coactivators, and
those that decrease it are called corepressors. Though, coregu-
lators form large protein complexes with SHRs, they are just
not “bridging” molecules that link SHR and the transcription
machinery rather, they often exhibit various enzymatic activi-
ties for example, acetylation, methylation, and ubiquitination,
that are required for the appropriate regulation of the target
gene transcription (Lonard and O’malley, 2007). In general, coac-
tivators contain an intrinsic histone acetyl transferase (HATs)
activity. Alternatively they may recruit HATs to the target gene
chromatin along with SHRs to enhance the transcriptional activ-
ity of the receptor. In contrast, corepressors recruit histone
deacetylases (HDACs) to the target gene chromatin to keep the
chromatin in closed conformation thus shutting off the target
gene transcription (Figure 1). The global actions of coregula-
tors involve chromatin modification and remodeling, initiation
of transcription, elongation of RNA chains, mRNA splicing,
mRNA translation, miRNA processing, and interestingly degra-
dation of the activated NR-coregulator complexes and termi-
nation of the transcriptional response (Lonard and O’malley,
2007). In vivo studies using knockout mouse models provided
evidence that several of these coregulators are important for
E2-dependent mammary growth and the same are discussed
here.
ER COREGULATORS, THE ORCHESTRATORS OF E2
SIGNALING
Because majority of breast cancers are ERα positive and coreg-
ulators proved to be crucial for ER transcriptional activity, an
increased interest in the field has led to the identification of
a large number of coregulators (Lonard and O’malley, 2006).
Deregulated expression of large number of coregulators is asso-
ciated with breast cancer development (Manavathi et al., 2013).
The first discovered coregulator of ERα is SRC-3/AIB1 (Onate
et al., 1995). So far large number of coregulators have been
FIGURE 1 | Coregulator action on ER signaling. Schematic
representation of the action of coregulators on ER activity is comprised of
three tiers. In the tier 1, coactivators facilitate ER interaction with RNA
Polymerase II complex to enhance the target gene transcription. On the
other hand, the corepressors affect ER interaction with RNA Polymerase II
complex to suppress the target gene transcription. In tier 2, various
post-transcriptional modifications (PTMs) that include phosphorylation,
methylation, acetylation, sumoylation, etc., of coregulators further impact
on their ability to modulate ER functionality. In tier 3, external signals like
growth factors and steroid hormones may influence the post-translational
modifications of coregulators. ERE, estrogen response elements.
identified for ERα, whereas very few coregulators are known for
ERβ (Lonard and O’malley, 2006). Though ERα and ERβ utilize
E2 as their physiological ligand, they have overlapping and dis-
tinct functions. This could be partly explained by their differential
utilization of coregulators. The different classes of ERα (hereafter
we referred as ER) coactivators include members of steroid recep-
tor coactivator (SRC)/p160 family, the histone acetyltransferase
cAMP responsive element binding protein (CREB)-binding pro-
tein (CBP)/p300, ATP-dependent chromatin remodeling com-
plexes like SWI/SNF, E3 ubiquitin-protein ligases and steroid
RNA activator (SRA) (Lonard and O’malley, 2006). Majority of
coactivators utilize specific motifs called NR boxes or LXXLL
motifs (X, any amino acid; L, Leucine) to mediate their inter-
action with ligand-binding domains of ER (Heery et al., 1997).
Conversely, corepressors inhibit ER-mediated gene transcription
through a direct interaction with unliganded ER or by utiliz-
ing corepressor nuclear receptor (CoRNR) box present in it or
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by competing with coactivators for ER binding (Hu and Lazar,
1999).
The intriguing question about the ER field is the presence
of many coregulators for ER (>200). It is reported that dif-
ferential expression of coregulators in many tissues account for
cell-specific regulation of E2 target gene expression (Misiti et al.,
1998; Smith and O’malley, 2004). This implies that the degree of
coregulator expression is critical to their ability to influence the
transcriptional potential of the ERs that allows fine-tuning of tar-
get gene transcription in response to E2 (Brisken and O’malley,
2010). Interestingly, the concentration of several coregulators of
ER is subjected to transcriptional regulation by E2, and in turn
these coregulators regulate the expression of ERs, thus operating
feedback mechanisms that are common in endocrine regulation
(Mishra et al., 2004). Various PTMs such as phosphorylation,
methylation, ubiquitination, SUMOylation and acetylation also
influence the activity of coregulators and, thereby target gene
expression (Lonard andO’malley, 2007; O’malley et al., 2008; Han
et al., 2009) (Figure 1). Combined or individual modifications on
a coregulator can bestow distinct activities for the same coregula-
tor. In this way, a repertoire of coregulators is generated in a cell so
that these regulatory molecules are used at appropriate time and
conditions.
ROLE OF ER COREGULATORS IN MAMMARY GLAND
DEVELOPMENT
Although the role of E2 in mammary gland development is well
established through endocrine disruption procedures, the precise
role of its cognate receptor ER in mammary gland development
is derived from mouse knockout studies. Disruption of Esr1 (ER)
gene in mouse led to complete abrogation of the mammary gland
development indicating that ER is indispensible for the mam-
mary gland development (Mueller et al., 2002; Mallepell et al.,
2006; Feng et al., 2007). Because ER-mediated activity depends
critically on its coregulator proteins, they are expected to play cru-
cial role in mammary gland development. Knockout approaches
were employed to address the role of coregulators in mammary
development. Distinct phenotypes such as embryonic lethality,
metabolic diseases, impaired reproduction and defects in mam-
mary gland development were evident upon complete ablation
of several ER coregulators (Lonard et al., 2007; Dasgupta et al.,
2014). The role of various coregulators in mammary gland devel-
opment is summarized in Figure 2. Mammary gland-specific
conditional knockouts are required for understanding the role of
coregulators whose complete deletion in mouse results in embry-
onic lethality. This helps to understand whether they indeed
participate inmammary gland development or not. In this review,
we will restrict our discussion to the findings till now that connect
coregulators to mammary gland development.
AIB/SRC FAMILY
The well characterized amplified in breast cancer (AIB)/steroid
receptor coregulator (SRC)/p160 family of coactivators appeared
to be involved in regulating uterine growth, embryo implanta-
tion, fertility and mammary gland development (Xu et al., 1998,
2000; Gehin et al., 2002; Nishihara et al., 2003). The three SRC’s,
SRC-1, 2, and 3, have been shown to coactivate ER signaling in
mammary epithelial and cancer cells. SRC coactivators contain
LXXLL motif which helps them to interact with AF-2 domain
of ER and, possesses an intrinsic histone acetyltransferase activ-
ity (Mcinerney et al., 1998). The typical mechanism of action by
these coregulators includes recruitment of secondary coactivators
such as p300, cAMP response element binding protein-binding
protein and coactivator-associated arginine methyltransferase 1,
which exhibits histone methyltransferase activity, on the target
gene promoters to enhance the ER-mediated transcription via
chromatin modification (Chen et al., 1999, 2000).
In vivo studies established that SRC-1 is required for normal
mammary ductal elongation and alveolar development (Xu et al.,
1998). Knockout (KO) mouse of Src-1 had normal body size but
showed decreased mammary ductal branching and alveologene-
sis. Further, Src-1 KO mice displayed moderate motor dysfunc-
tion, delayed development of Purkinje cells, control of energy
balance, loss of skeletal response to E2, altered hypothalamic-
pituitary-adrenal axis function and hepatic malfunction (Xu
et al., 1998; Nishihara et al., 2003). The specific effects on mam-
mary gland in Src-1 KO mice are that the extent of ductal
branching as well as the number of branches was substantially
reduced in the mammary glands, spreading of ductal is only half
the area of themammary fat pad and the alveoli that are much less
developed in terms of number and size, though milk production
is normal. It implies that Src-1 is an important coregulator of ER
for ductal branching at puberty and is required for alveologenesis
during pregnancy.
Similar to Src-1 KO mice, the disruption of Src-2 (GRIP-1 or
TIF2) led to severe abnormalities in reproductive function (Gehin
et al., 2002). Surprisingly, mammary glands from virgin, pregnant
and nursing Src2 null females were histologically and functionally
normal suggesting that Src-2 is not required for early postnatal
development of the mammary gland. Interestingly, SRC-2 pro-
tein is expressed in mammary epithelial cells that are positive
for progesterone receptor (PgR) indicating that mammary Src-2
may occupy a crucial role in progesterone-mediated prolifera-
tive developments (Mukherjee et al., 2006). Accordingly, Src-2KO
mice epithelium do not undergo proliferation even in the pres-
ence of mammary PgR clearly implying that Src-2 is indispensable
in progesterone-induced mammary ductal side branching and
alveologenesis but not for E2 regulated ductal development. Thus,
SRC-2 does not integrate into ER signaling in vivo directly but
could be through PgR signaling.
Similar to the other SRCs, SRC-3 (AIB1, ACTR, and TRAM-1)
is also critical for mammary gland development. Src-3 KO
mice display retarded mammary gland development, dwarfism,
delayed puberty and reduced female reproductive function (Xu
et al., 2000). Tissue expression analysis suggested that Src-3 is
highly expressed in the TEBs and epithelial cells of mammary
gland. Despite its expression in TEBs, Src-3 is not required for
TEBs growth. It seems that the retardation of mammary duc-
tal growth in the Src-3 null mice is due to low levels of E2
(Xu et al., 2000). Therefore, E2 therapy successfully rescued
the growth deficiency of mammary ducts suggesting that Src-
3 is not essential for the E2-stimulated ductal growth in virgin
mice despite of its high expression in mammary gland epithe-
lial cells. But during alveolar development, Src-3 is required for
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FIGURE 2 | Role of coregulators and pioneer factors in mammary gland
development. Schematic representation of the role of various coregulators
and pioneer factors of ER on different stages of mammary gland
development. The thin arrows points to the developmental defects at these
stages of mammary gland development due to the loss of the expression of
respective coregulator. Whereas the inhibitory lines (-|) points to the
suppressive effect of the respective coregulator at the indicated stages of
mammary gland development. LN, lymph node; TEB, terminal end buds.
progesterone-stimulated cell proliferation and glandular differ-
entiation (Xu et al., 2000). The comparative summary indi-
cates that the physiological role of SRCs is different from
one another and proves the diversity among coactivator family
members.
BRCA1
Breast cancer associated protein 1 (BRCA1), a tumor suppressor,
was initially identified as a gene predisposed to breast and ovar-
ian cancers (Miki et al., 1994). Rosen group identified BRCA1
as a transcriptional inhibitor of ER (Fan et al., 1999), bringing
the first link between ER and BRCA1. BRCA1 inhibits ER tran-
scriptional activity through direct interaction between the BRCA1
and ER proteins and partly, by regulating the expression of p300,
a transcriptional coactivator for ER (Fan et al., 2001, 2002).
The N-terminal region of BRCA1 interacts with AF-2 domain of
ER, while the carboxyl-terminus mediates the repressor function.
For instance, BRCA1 inhibits E2-inducible secretion of vascu-
lar endothelial growth factor (VEGF) (Zheng et al., 2001; Kawai
et al., 2002). Mechanistic studies indicate that BRCA-mediated
inhibition of ER transcriptional activity relies on the ability of
BRCA1 to mono-ubiquitinate ER which in turn is dependent on
the acetylation status of ER (Eakin et al., 2007). Interestingly,
BRCA1 is upregulated in response to E2 in mammary epithelial
cells and, BRCA1 in turn transcriptionally regulates ER positively
by associating with OCT-1, a transcription factor. This implies the
existence of a positive feedback mechanism that regulates func-
tional interaction between ER and BRCA1 in breast cancer cells
(Spillman and Bowcock, 1996). BRCA1 regulates ER expression
positively, hence loss of BRCA1 can lead to ER-negative pheno-
type providing a molecular basis for the loss of ER expression in
the majority of BRCA1 mutant cancers (Hosey et al., 2007).
The physiological link between BRCA1 and mammary gland
development was established using knockout mouse models.
Brca1 deletion inmice using tissue-specific conditional knockouts
resulted in impaired mammary development (Xu et al., 1999).
The Brca1−/− mammary glands are smaller due to increased
cellular apoptosis and, they also display abnormal ductal mor-
phogenesis. Initial studies suggested an important developmental
role for the murine homolog of BRCA1 in the regulation of cell
proliferation and differentiation. In consistent with these results,
in vitro studies using the HC11 murine mammary epithelial cell
line showed that Brca1 mRNA and protein levels increased dur-
ing lactogenic differentiation (Rajan et al., 1997). Loss of BRCA1
results in impaired differentiation while increased proliferation
of MCF10A (a human mammary epithelial cell line), further sug-
gesting its strong association with cellular differentiation. These
cellular differentiation functions are probably due to the fact that
BRCA1 transcriptionally regulates a number of basal and lumi-
nal terminal differentiation markers that define a cell fate within
the mammary gland (Hosey et al., 2007; Gorski et al., 2009).
Recent studies show that BRCA1 indeed promotes differentiation
along the luminal lineage in coordination with Notch signaling
(Buckley et al., 2011). Furthermore, BRCA1 is also shown to
collaborate with GATA3 to regulate genes crucial for the mainte-
nance of luminal lineage (Kouros-Mehr et al., 2006; Tkocz et al.,
2012). It thus implies that BRCA1 is required for luminal cell
differentiation during mammary gland development.
CITED-1
CITED-1, a CBP/p300-binding nuclear protein, functions as
a selective coactivator for E2-dependent transcription. In ER-
positive breast cancer cells, CITED-1 binds directly to ER through
its transactivation domain and sensitizes the cells to E2 by
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stabilizing the E2-dependent interaction between p300 and ER
(Yahata et al., 2001). CITED-1 coactivator function is gene-
specific as it doesn’t induce ER signature genes such as pro-
gesterone receptor, PgR or pS2, rather it upregulates TGF-β in
MCF-7 cells (Yahata et al., 2001). Thus the induced TGF-β in turn
modulates the proliferative action of E2 (Ewan et al., 2002).
Gene profiling analysis in different regions of mammary duc-
tal tree identified CITED-1 as one of the selectively expressed
genes in a subset of luminal and preluminal epithelial cells in the
pubertal mammary gland (Howlin et al., 2006). This led to the
possibility that CITED-1 may mediate signals in the E2-TGF-β
regulatory axis. During puberty, CITED-1 localizes to the lumi-
nal epithelial cell population of the mammary ducts and the body
cells of the TEBs. Characterization of Cited-1 KO mice revealed
that Cited-1 is required for ductal growth during puberty as
homozygous null mutant’s exhibited retarded mammary ductal
growth. The other prominent Cited-1 KO’s mammary pheno-
type was altered ductal morphology with dilated and spatially
restricted branches (Howlin et al., 2006). These defects in mam-
mary glands of Cited-1 KO are attributed to alterations in the
transcription of a number of key downstream targets of both
E2 and TGF-β. Further, loss of EGFR/ErbB2 ligand (amphireg-
ulin) expression, one of the prime targets of E2, was observed in
Cited-1 null mice. It thus implies the potential maintenance of
the ER-CITED-1 co-regulated signaling pathway in the pubertal
mammary gland.
CYCLIN D1
Cyclin D1, encoded by Ccdn1 gene which is located on chromo-
some 11q13, forms the regulatory subunit of cyclin-dependent
kinases 4 (CDK4) and, was found to be overexpressed in 50%
of breast cancers (Ormandy et al., 2003). It is shown to coacti-
vate ER-dependent transcription in a ligand-independentmanner
(Zwijsen et al., 1998; Lamb et al., 2000). Cyclin D1 competes
with BRCA1, which represses ER transactivation, for binding
to hinge region of ER thereby it display coactivator function
(Wang et al., 2005). In contrast, genome-wide expression pro-
filing in Ccnd1 KO mice treated with E2 demonstrated that
cyclin D1 determines large number of E2-responsive genes in vivo
(Casimiro et al., 2013). Further, in cyclin D1-silenced (by RNAi)
MCF7 cells, it was evident that cyclin D1 is required for E2-
mediated gene expression in vitro. These results are further
substantiated by genome-wide chromatin immunoprecipitation-
sequencing (ChIP-Seq) analysis. It was observed that cyclin D1
indeed binds to the E2-ER target gene chromatins, ErbB3, EphB3,
and their ligands, amphiregulin and matrix metalloproteinase.
The above facts suggest that cyclin D1 mediates E2-dependent ER
transactivation and is required for convergence of ER and growth
factor signaling at a common cis-element of growth factor genes.
Though deletion of Ccdn1 in mice is not lethal, Ccdn1 abla-
tion results in the arrest of mammary gland development before
lobuloalveolar development, thereby underscoring its definitive
role in this process (Fantl et al., 1999). The defects in the mam-
mary gland are due to loss of expression of several E2- and cyclin
D1-depenndent genes. In Ccdn1 KO pregnant mice, the glands
do not open due to lack of lobuloalveolar growth. The epithelial
cell-specific overexpression of Ccdn1 in mice leads to mammary
carcinoma indicating that the optimal concentration of Ccdn1 is
required for proper development of mammary gland (Wang et al.,
1994). This could partly explain why cyclin D1 overexpression is
associated with 50% of breast cancers.
E6-AP
E6-associated protein (E6-AP) is a HECT (homologous to E6-
associated protein carboxy-terminal) domain containing E3 ubiq-
uitin ligase that is known to act as a coactivator for ER, PR
and RXRα (Nawaz et al., 1999). E6-AP possesses two indepen-
dent discrete functions: coactivation of ER and ubiquitin-protein
ligase activity (Ramamoorthy and Nawaz, 2008). Being a compo-
nent of the ubiquitin-proteasome pathway, it was presumed that
E6-AP may regulate the dynamics of steroid hormone receptor-
mediated transcription by modulating the degradation of the
transcriptional complexes. However, this still remains elusive as
ER stability is known to correlate with E6-AP expression (Gao
et al., 2005). Down regulation of E6-AP leads to increased ER
levels. On the other hand, E6-AP enhances the transcriptional
activity of ER by recruiting chromatin modifiers like p300 at ER
target gene promoters (Catoe and Nawaz, 2011). Furthermore,
phosphorylation of ER at tyrosine 537 (Y537) by Src kinase is
shown to potentiate ER binding to the ubiquitin E6-AP, subse-
quent ER ubiquitination, target gene activation and ultimately
loss of ER function (Sun et al., 2012). This also suggests that a
delicate balance between coactivator function and degradation
activity of E6-AP, which attributes to its role in mammogenesis
as well as breast cancer development.
E6-ap KOmice display reduced gonadal size suggesting its role
in fertility. Though E6-AP is expressed in mammary gland, E2
and progesterone-stimulated growth of virgin mammary gland
was not compromised by E6-ap ablation, suggesting that E6-AP
is not important in mediating steroid hormone actions in vivo
(Smith et al., 2002). In another study, it was shown that over-
expression of E6-AP (WT) results in impaired mammary gland
development. Overexpression of defective E6-AP (C833S) (an
ubiquitin ligase-defective), or the loss of E6-ap increased lat-
eral branching and alveolus-like protuberances in the mammary
gland. The mammary phenotypes observed in the E6-AP trans-
genic are attributed to the alteration in the level of progesterone
receptor-B (Pgr-B), an ER target gene (Ramamoorthy et al., 2012).
These studies indicate that E6-AP inhibits lateral branching
during mammary gland development.
HER4/4ICD
The HER4/ErbB4 is an EGFR family member that is proteolyt-
ically processed at the cell surface to release the cytosolic side
fragment i.e., intracellular domain (4ICD), which independently
impacts a variety of functions including acting as a coactivator
for ER (Naresh et al., 2006; Zhu et al., 2006). Its functions are
found to be location specific. For example, nuclear 4ICD in tumor
cells acts as a potent ER coactivator leading to E2-stimulated
proliferation of breast cancer cells, whereas in mammary gland,
it regulates differentiation and lactation via STAT5 pathway
(Williams et al., 2004). Cytosolic 4ICD accumulates in mito-
chondria where it regulates apoptosis (Naresh et al., 2006; Zhu
et al., 2006). Endogenous 4ICD interacts with and potentiates ER
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transactivation in breast cancer cells as loss of 4ICD expression
decreases ER-mediated transactivation function, whereas overex-
pression of 4ICD in the MCF-7 cell line increased E2 stimulation
of ERE reporter activity (Zhu et al., 2006). Interestingly, the
E2 stimulation of ER drives nuclear translocation of 4ICD. The
nuclear localized ER/4ICD complex then selectively is recruited
to E2-inducible gene promoters. The 4ICD displays gene-specific
coactivation functions toward ER as it coactivates transcription
of progesterone receptor (PgR) and stromal cell-derived factor
1 (SDF-1) but not trefoil factor 1 precursor (pS2) (Zhu et al.,
2006). Although substantial evidence supports that 4ICD func-
tions as a transcriptional coactivator, the precise mechanism of
action toward ER is not known. Interestingly, Her4 itself is an E2-
inducible gene and, ER/4ICD complex recruits to Her4 promoter
in response to E2. Because, Her4 expression is also shown to be
required for the growth-promoting action of E2 in breast cancer
cells, it provides evidence for the involvement of an autocrine sig-
naling in breast cancer cells. This suggests that 4ICD is a unique
coregulator of ER that directly couples extranuclear and nuclear
E2 actions in breast cancer cells (Zhu et al., 2006).
The in vivo role of 4ICD on ER functions is assessed using
knockout mice without Her4 which is the mature form of 4ICD.
Her-4 KO in mice causes embryonic lethality at day 11 due to
defects in heart development (Tidcombe et al., 2003). The res-
cued Her4 mutant mice are viable and fertile, but they do not
lactate, indicating the role of Her-4 in mammary gland devel-
opment. Progesterone receptor (PgR) is known to be required
for lobuloalveolar development in mammary gland and, E2 reg-
ulates expression of Pgr-A, whereas expression of Pgr-B is E2
independent (Tanos et al., 2012). Consistent with a role for 4ICD
in E2-regulated PgR expression in vitro, PgR-A, but not PgR-
B, expression was abolished in mammary glands of Her4-null
mouse. The study by Risicki et al., provided further evidence that
4ICD is nuclear localized in mammary epithelium and acts as
coactivator in the mammary development (Rokicki et al., 2010).
In summary, 4ICD is a physiologically important ER coactiva-
tor and it cooperates with ER to potentiate Pgr expression in the
normal breast.
MED1
MED1, also known as DRP205/TRAP220/PBP, is one of the coac-
tivators of a large ∼1.6MDa protein complex called “Mediator,”
which is a part of the RNA polymerase II holoenzyme. “Mediator”
bridges the communication between transcriptional activators
and RNA polymerase II to influence the transcription (Malik
et al., 2004). Therefore, MED1 has been shown to act as a coacti-
vator for ER. The LXXLLmotifs of MED1 are crucial for its inter-
actions with nuclear receptors and for nuclear receptor-mediated
transcription of target genes (Jiang et al., 2010).
To understand its functional significance in steroid hormone
receptor action and mammary gland development, Med1 LXXLL
motif-mutant knockin (KI) mice (Med1KI/KI) were generated
since complete deletion of Med1 leads to embryonic lethality.
Med1KI/KI mice were fertile and normal but exhibited profound
abnormalities at the virgin stage indicating defects in pubertal
mammary gland development (Jiang et al., 2010). The defects
observed in mammary gland development in Med1KI/KI mice
are attributed to significant impairments both in ER-dependent
gene expression in mammary epithelial cells and in E2-stimulated
mammary ductal growth further indicating the significance of
LXXLL motifs in coactivator function. Because Med1 gene abla-
tion in mice led to embryonic lethality, a recent study conducted
on the Med1/Med24 double heterozygous KO (dhKO) mice,
which are viable, addressed the role of Med1 in mammary gland
development (Hasegawa et al., 2012). Mammary glands from
Med1/Med24 dhKO mice showed profound impediment in duc-
tal branching during puberty, while in single haplo-insufficient
mice, glands developed normally. These phenotypic differences
point out to the possibility that other subunits of “Mediator”
complex are engaged. Further, DNA synthesis of both luminal and
basal cells were impaired in double mutant mice. The expression
of ER-dependent genes such as E2F1 and cyclin D1, which pro-
mote progression through the G(1)/S phase of the cell cycle, was
attenuated. These studies established the coactivator functions
of “Mediator” complex for ER in normal mammary epithelial
cells.
MTA1 FAMILY
The metastasis-associated proteins are a small family of coreg-
ulators which comprises of MTA1, MTA2, MTA3, and MTA1s.
Individual MTAs takes part as critical components of nuclear
remodeling and deacetylation (NuRD) complex, and therefore
represses target gene expression through deacetylation of his-
tones in the chromatin (Manavathi and Kumar, 2007). The first
target gene identified for MTA1/NuRD complex is ER and the
ligand-dependent transactivation functions of ER are repressed
in cultured breast cancer cells (Mazumdar et al., 2001). TheMta1
KO mice are viable but the information about the mammary
gland development in these mice is obscure (Manavathi et al.,
2007). Mice overexpressing MTA1 (MTA1-Tg) under the control
of themousemammary tumor virus (MMTV) promoter long ter-
minal repeat was used to understand its role in mammary gland.
Extensive side branching and precocious differentiation due to
increased proliferation of ductal and alveolar epithelial cells was
observed in mammary glands of MTA1-Tg virgin mice (Bagheri-
Yarmand et al., 2004). The mammary glands of virgin transgenic
mice resemble those from wild-type mice in mid-pregnancy but
have shown inappropriate expression of β-casein, cyclin D1 and
β-catenin proteins. Interestingly, progesterone receptor-B isoform
(Pgr-B) expression was down regulated, whereas the progesterone
receptor-A (Pgr-A) isoform was upregulated in MTA1-Tg mice.
Increased expression of Pgr-A resulted in upregulation of PgR
target genes such as Bcl-XL and cyclin D1 leading to delayed invo-
lution. The results of the study indicated the possible role of
MTA1 in mammary gland during branching morphogenesis and
alveologenesis.
MTA1s, the short variant of MTA1, has been shown to sup-
press ER transcription by sequestering the receptor into the
cytoplasm (Kumar et al., 2002). MTA1s role in mammary gland
development was analyzed by transgenic approach by the same
group that generated the MTA1 transgenic mice (Kumar et al.,
2010). MTA1s-Tg mammary glands displayed extensive hyper-
branching and increased proliferation of ductal and alveolar
epithelial cells, which mimicked the phenotypic changes found
Frontiers in Cell and Developmental Biology | Cellular Endocrinology August 2014 | Volume 2 | Article 34 | 6
Manavathi et al. ER coregulators and pioneer factors in mammary gland
in the Wnt-Tg mice. Overexpression of MTA1s in HC11, a lacto-
genic differentiation cell line, activated Wnt1 signaling through
MAPK and GSK3-beta pathways, resulting in increased stabi-
lization and nuclear accumulation of β-catenin. Furthermore,
mammary glands from the virgin MTA1s-Tg mice showed ductal
hyperplasia and ductal carcinoma in situ. These findings indicate
a possible requirement of MTA1s in mammary gland devel-
opment during ductal branching and alveologenesis similar to
MTA1.
MTA3 also forms a cell type-specific Mi2–NuRD complex.
MTA3 has been shown to act as a direct transcriptional repres-
sor of Snail, a master regulator of the epithelial-to-mesenchymal
transition (EMT) (Fujita et al., 2003). The role of MTA3 in
mammary gland development was explored using a transgenic
approach (Zhang et al., 2006). Targeted overexpression of Mta3
in the mouse mammary gland resulted in a pronounced defect
in ductal side branching both in virgin mice and in the early
stages of pregnancy, a contrasting phenotype observed in MTA1-
Tg mice. Though the mammary glands of both MTA3-Tg mice
and wild type mice were similar at early developmental stages,
drastic reduction in secondary and tertiary ductal side branch-
ing were observed in the Tg mice. This hypobranching phenotype
of mammary gland in MTA3 was comparable to the defective
branching in Wnt4 KO mice (Brisken et al., 2000). Further,
molecular analysis revealed that the reduced ductal branch-
ing is due to suppression of Wnt4 expression by MTA3-NuRD
complex (Zhang et al., 2006). The comparative summary indi-
cates contrasting roles for MTA1 and MTA3 in mammary gland
development.
PROHIBITIN
Prohibitin (PHB) and REA (Repressor of ER activity), also
known as PHB2, belong to a family of proteins that contain
an evolutionarily conserved domain, the prohibitin homology
domain. PHB plays a diverse role in cellular differentiation,
anti-proliferation and morphogenesis (Chowdhury et al., 2014).
Overexpression of PHB in breast cancer cells suppresses the ER
transcriptional activity, whereas depletion increases the expres-
sion of ER target genes (He et al., 2008). PHB interacts with
HDAC1 through its coiled domain which partly explains its
corepressor activity on ER transactivation functions (He et al.,
2008).
The role of PHB in mammary gland development was inves-
tigated in Phb+/− heterozygous mice since complete deletion of
Phb gene leads to embryonic lethality (He et al., 2008). PHB
being a corepressor of ER in cultured cells, it is expected to
show a hyper proliferative phenotype in the mammary glands of
Phb+/− mice. Consistent with this notion, Phb+/− mice displayed
increased alveolar lateral budding and ductal side-branching in
the hormone-treated mammary gland. The increased level of
cyclin D1, a direct target of ER, in Phb+/− mice compared to
wild type mice was attributed to this hyper-proliferative state in
Phb+/− mice (He et al., 2008). Accelerated mammary growth
in response to steroid hormone treatment was also seen in
Phb+/−mice suggesting an important in vivo role for the PHB
as a corepressor for ER in controlling steroid-induced mammary
morphogenesis.
REA
Repressor of ER activity (REA) was initially identified as an
ER interacting protein using dominant negative ER as bait
in two-hybrid screening assays (Montano et al., 1999). REA
displays its corepressor functions by enhancing the binding
of anti-estrogens such as SERMs to ER. Though REA con-
tains an LXXLL motif near its N-terminus, this motif does
not participate in the binding of REA to ER. Rather the
C-terminal half of REA interacts with ligand-binding domain
of ER. REA functionally competes with coactivators like SRC-
1 to modulate ER transcriptional activity which partly explains
the corepressor activity of REA on ER-mediated transcription
(Delage-Mourroux et al., 2000). Further, it was shown that
PTalpha (Prothymosin), another coactivator of ER, antagonizes
REA inhibitory action toward ER transcriptional activity by
replacing the repressive REA protein away from ER (Martini et al.,
2000).
Deletion of both the alleles of REA (PHB2) results in
embryonic lethality similar to PHB, whereas heterozygous mice
(Rea+/−) display mammary ductal elongation in virgin animals
and, increased lobuloalveolar development during pregnancy
followed by delayed mammary gland involution after weaning
(Mussi et al., 2006). Since, REA displays corepressor activity on
ER, these morphological phenotypes of Rea+/− mice reflected
the increased cell proliferation and ER transcriptional activities.
Recently, tissue-specific conditional KO approach was used to
investigate the consequences of complete loss of Rea in mam-
mary gland (Park et al., 2011). Conditionally deleting one allele
or both alleles of the Rea gene at different stages of mam-
mary gland development resulted in different mammary phe-
notypes (Park et al., 2011). During puberty, mice homozygous
null for Rea in the mammary gland showed severely impaired
mammary ductal elongation and morphogenesis, whereas mice
heterozygous for Rea displayed accelerated mammary ductal
elongation and increased numbers of TEBs. In addition, Reamice
showed an up-regulation of amphiregulin, the major paracrine
mediator of E2-induced ductal morphogenesis. During preg-
nancy and lactation, mice with homozygous Rea gene deletion
in mammary epithelium showed a loss of lobuloalveolar struc-
tures and increased apoptosis of mammary alveolar epithelium,
leading to impaired milk production and significant reduc-
tion in growth of their offspring. These studies imply that
REA is essential for mammary gland development and, has a
gene dosage-dependent role in the regulation of stage-specific
physiological functions of the mammary glands (Park et al.,
2011).
RIP140
Receptor-interacting protein 140 (RIP140) was initially identified
as an ER interacting factor in vitro (Cavailles et al., 1995). Later, it
was found to be involved in various regulatory feedback loops and
inhibitory cross talks involving several nuclear receptors (White
et al., 2004). Though, RIP140 was initially characterized as a
nuclear receptor coregulator based on its ability to coactivate
steroid hormone receptors, subsequent studies indicated that it
can also act as a corepressor (Cavailles et al., 1995; Nautiyal et al.,
2013). RIP140 inhibits ER-dependent transcription by competing
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with coactivators and, also by recruiting histone deacetylases
(HDACs) to target gene chromatin (Castet et al., 2004).
RIP140 is expressed in both mammary epithelium and stroma,
and its role in the development of mammary gland was assessed
using knockout and transgeneic approaches. At puberty, Rip140
KO mice lacked TEBs at the tips of the ducts, but at matu-
rity (5 months old), in Rip140 KO mice the mammary tree was
relatively less branched as compared to heterozygous and wild
type mice (Nautiyal et al., 2013). On the other hand, Rip140
overexpressing mice exhibited large primary ducts, hyperplasic
growth and TEBs. Further, Rip140-Tg mice developed larger and
denser alveolar structures inmammary epithelium indicating that
Rip140 can influence alveologenesis. The molecular mechanism
of the role of Rip140 in mammary gland development has been
attributed to its function as a corepressor that recruited with ER
to its target gene promoters includingAreg, Pgr,Ccnd1, andGata3
(Nautiyal et al., 2013). In summary, expression of RIP140 in both
mammary epithelial and stromal compartments is required for
ductal elongation during puberty and silencing of RIP140 expres-
sion leads to a complete loss of the mammary epithelium. These
in vivo studies thus imply that RIP140 is certainly a coregulator
for ER.
THE ER SIGNALING IN CELL FATE DECISIONS
E2 SIGNALING AND ER STATUS IN MAMMARY STEM CELLS (MaSC)
Cell fate is simply defined as cellular specification or determi-
nation with a unique character and behavior. Tissue transplan-
tation experiments combined with lineage tracing approaches
using mouse models provided significant advancement in under-
standing the mammary cell fate (Stingl, 2009; Van Amerongen
et al., 2012). The present understanding suggests that a func-
tional epithelium can be regenerated from mammary stem cells
upon transplantation into cleared fat pads. Mammary epithe-
lium contains progenitors that give rise to ductal system and
contractile myoepithelium because of their pluripotent capac-
ity (Rosen, 2012). Two main lineages of mammary epithelium,
namely luminal epithelial cells and basal myoepithelial cells, gen-
erate a functional epithelium. The luminal cells are the ducts
that form the milk-secreting cells of the alveoli, whereas the
myoepithelial cells that form a layer on the luminal epithelium
along the ducts helps in milk secretion during lactation. The
luminal cells may be either ER positive (ER+) or ER nega-
tive (ER−) but the luminal progenitors are predominantly ER−,
with a small number of them being ER+ (Regan et al., 2012).
The ER+ cells are hormone responsive and support paracrine
signaling in luminal epithelium, whereas the ER-luminal cells
include the milk secretory cells (Regan et al., 2012). Therefore,
all three populations of cells that include myoepithelial, ER+
and ER− luminal cells constitute the differentiated cells of mam-
mary epithelium. Both myoepithelial and luminal lineages can
also be derived from the TEBs or TEBs implying that TEBs
carry stem cells and progenitor features (Srinivasan et al., 2003).
Mammary stem cells require estrogen signaling as ovariectomy in
mice markedly diminishes mammary stem cells (MaSC) number
and their outgrowth potential in vivo indicating a role for E2 in
self renewal and maintenance of stemness (Asselin-Labat et al.,
2010).
PIONEER FACTORS IN MAMMARY CELL FATE
In general, the cell fate decisions are driven by tissue-specific
transcription factors (TFs) based on the cell fate determination
signals. A set of transcription factors forming a genetic network
with a defined regulatory system controls cell fate determination
and subsequently organ development. A well orchestrated net-
work of interactions between such transcription factors and their
associated proteins play a regulatory role during organogenesis
and development (Davidson and Erwin, 2006; Raouf et al., 2008).
Emerging studies have shown that ER functionally interacts with
“pioneer factors” in a coordinated fashion to control the mam-
mary gland cell fate (Jozwik and Carroll, 2012). “Pioneer factors”
are transcription factors that can directly bind to condensed chro-
matin and can bring either positive or negative transcriptional
outcomes by recruiting other transcription factors and/or histone
modification enzymes (Magnani et al., 2011b; Jozwik and Carroll,
2012). In the recent past, FOXA1, GATA3, PBX1 and AP2gamma
are characterized as pioneer factors of ER that play crucial role in
decisions regarding fate of cells in mammary gland development
(Schuur et al., 2001; Kouros-Mehr et al., 2006; Magnani et al.,
2011a).
FOXA1
FOXA1, a member of the forkhead transcription factor family,
participates in pioneer function of the genome regulation (Sekiya
et al., 2009). FOXA1 is the first pioneer factor identified for the
ER and it co-expresses with ER during mammary gland develop-
ment, primary breast tumors and cell lines (Carroll et al., 2005;
Bernardo et al., 2010). Chromatin binding studies revealed that
FOXA1 binds at more than 50% of ER binding sites suggesting
that FOXA1 is a key regulator of ER functions in mammary gland
development (Hurtado et al., 2011).
FOXA1 is expressed in TEBs, particularly in a subset of lumi-
nal cells that are CD61+, while it is not expressed in myoepithelial
cells (Bernardo et al., 2010). The pattern of expression of FOXA1
matches with ER in the pubertal gland. Because of its critical role
in regulation of ER transcription functions and similarity in the
expression pattern with ER, KO mouse studies revealed that defi-
ciency of Foxa1 in mouse leads to defects in hormone-induced
mammary ductal invasion associated with a loss of TEB forma-
tion (Bernardo et al., 2010). It implies that FOXA1 is essential for
the ductal outgrowth during puberty. However, Foxa1 expression
is not required for embryonic development of the mammary duc-
tal rudiment similar to ER. Nevertheless, analysis of mammary
glands in Foxa1 null mice revealed that it is not important for
alveologenesis as Foxa1 null glands could form milk-producing
alveoli which are unlikely in Esr1 null mice. This suggests that
Foxa1 functions are probably restricted to ductal epithelium and
independent of alveologenesis. Because of the similarities between
the expression pattern and functions in mammary gland, tran-
scriptional interaction between FOXA1 and ER was verified. This
analysis indicated that FOXA1 regulates ER expression in lumi-
nal cells by directly associating at 10 distinct regions of the Esr1
gene, with five sites in the promoter region and five in intragenic
regions (Bernardo et al., 2010). It implies that FOXA1 contributes
to ER functionality and mammary cell fate by modulating the
basal expression and functional activity of ER.
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GATA3
GATA3 is a member of GATA transcription factors that partic-
ipate in development of various organs in the body (Ho and
Pai, 2007). Recent reports suggest a pivotal role for GATA3 in
mammary gland morphogenesis, particularly in luminal cell dif-
ferentiation (Kouros-Mehr et al., 2006; Asselin-Labat et al., 2007).
GATA3 was identified as highly enriched transcription factor in
a microarray screening of mammary epithelium (Kouros-Mehr
et al., 2006). During embryonic development, GATA3 expression
is detected at E12.5 day in primordial mammary buds (Asselin-
Labat et al., 2007) and is confined only to mammary epithelial
layer, but not in myoepithelium. Its restricted expression to lumi-
nal cell lineages indicates a potential role in the regulation of
epithelial cell phenotype of mammary gland development. In
consistent with its expression, deletion of Gata3 results in severe
defects in mammary development due to failure in TEB forma-
tion during puberty. This phenotype is similar to that observed
in loss of ER and it can be further attributed to the failure of
the expansion of the luminal progenitor population (Kouros-
Mehr et al., 2006). During pregnancy, GATA3 seems to participate
in luminal epithelial differentiation required for lobuloalveolar
development. The targeted deletion of Gata3 from progenitor
cells blocks luminal cell differentiation, whereas forced expression
of GATA3 in mammary stem-cell-enriched populations promotes
differentiation into luminal cells. These studies strengthen the
fact that GATA3 is required not only to maintain the luminal
epithelial lineage, but also in the determination of their cell fate
(Asselin-Labat et al., 2007).
An intriguing question is that how are GATA3 functions
related to ER? Similar to Esr1 KO mice, conditional deletion of
Gata3 led to the impairment in the TEBs formation suggesting
a functional overlap between these two factors. Although GATA-
3 and ER pathways may have few non-overlapping functions in
mammary luminal cells, FOXA1 bridges the link between ER
and GATA3 (Kouros-Mehr et al., 2008). The GATA3 functions
are truly integrated into E2 signaling pathway as both of them
regulate each other’s expression in luminal cells (Kouros-Mehr
et al., 2006). GATA3 regulates FOXA1, which in turn mediates
ER expression. Further, ER induces GATA3 expression in lumi-
nal cells implying that there is an interdependence of FOXA1,
ER and GATA3 in the maintenance of luminal cells (Figure 3).
Not only that these three transcription factors depend on the
transcription of the other, they also colocalize at genomic sites
after ligand stimulation results in the formation of a tripartite
enhanceosome complex of ERα, FOXA1, and GATA3. This com-
plex further ensures the optimal transcriptional activation by
recruiting RNA ploII and p300 to the target gene chromatin
(Kong et al., 2011). FOXM1, a forkhead transcription factor,
is shown to down regulate GATA3 expression through methy-
lation of the GATA3 promoter in association with DNMT3b,
a DNA methyl transferase. Therefore, FOXM1 promotes lumi-
nal proliferation by opposing GATA3-mediated luminal differ-
entiation in the mammary gland (Carr et al., 2012). Foxm1 is
an E2 inducible gene (Millour et al., 2010). Therefore, Foxm1
induction by E2-ER may balance the functional interaction
between ER and GATA3 during mammary gland. Taken together,
an intricate network of transcription factors involving GATA3,
FIGURE 3 | Interdependence of pioneer factors and ER specifies
mammary cell fate. Schematic representation showing the interplay
among ER, GATA3, FOXA1, and FOXM1 in mammary gland cell fate. GATA3
and ER regulate each other’s transcription positively. GATA3 also regulate
FOXA1 transcription and FOXA1 in turn upregulates ER in epithelial cells.
ER transcriptionally upregulates FOXM1 and FOXM1 in turn down regulates
GATA3. Luminal lineage specific factors such as FOXA1, GATA3, and ER
specify the fate mammary progenitor cells and promote their differentiation
into luminal epithelial cells.
FOXA1, FOXM1, and ER dictates the fate of the mammary cell
(Figure 3).
CONCLUDING REMARKS
Considering the significant role played by coregulators in ER
action, investigation on identification and characterization of new
coregulators for ER continues to be an interesting area of research.
On the other hand, knowledge on the intricate mechanisms that
underlie the coregulator-mediated actions on ER signaling is
rapidly expanding. Although, the in vitro roles of coregulators on
ER functionality and cellular functions are determined, informa-
tion available on the in vivo roles for ER coregulators is limited,
considering the large number of known coregulators for ER. This
could be due to the fact that complete ablation of the genes of sev-
eral coregulators led to embryonic lethality. Therefore, in future
there is a demand for the utilization of mammary gland-specific
conditional KO approach in murine models to address this issue.
In vivo studies using murine KO models indicated that coregu-
lators like SRC-3, CITED-1 and cyclin D1, and pioneer factors
such as FOXA1 and GATA3 are important for the development
of pubertal mammary gland. Some coregulators appear to be
important in the later stages of mammary gland development,
it can be implied that coregulators do not follow a thumb rule
in mammary gland development. Balanced expression through
interdependency mechanisms among ER, FOXA1, and GATA3
specifies fate of the luminal cell. Considering their established role
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in mammary gland development and breast cancer, mutant mice
models of these coregulators can be further explored for clinical
studies in the future. Obtaining the blueprint of all the coregula-
tors and their role in mammary gland development may further
offer therapeutic strategies to develop coregulator-based therapies
to treat breast cancers.
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